Clinical Trial Update: A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD [Phase 2]

View source ↗

Summary

A Phase 2a trial evaluating ALN-PNP with and without a GLP-1 receptor agonist for homozygous PNPLA3-related MASLD is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatotic Liver Disease

Drugs mentioned

• ALN-PNP (ALN-PNP)
• GLP-1 receptor agonist (unspecified)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Phase 2 | Status: NOT_YET_RECRUITING